Eton Pharmaceuticals Inc. (ETON) Tops Q4 EPS by 1c

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q4 EPS of $0.19, $0.01 better than the analyst estimate of $0.18. Revenue for the quarter came in at $21.3 million versus the consensus estimate of $21.96 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• BTIG Upgrades Tidewater Inc (TDW) to Buy, 'Increasing Activity Set To Push Dayrates Higher in Key Basins'
• JPMorgan Downgrades Li Ning Co. Ltd. (2331:HK) (LNNGF) to Neutral